My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

Merck & Company Inc. (MRK) — RQD Stock Rating Cockpit

$132.74 -3.66% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $131.61

Merck & Company Inc. (MRK) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $327.24B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MRK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, Merck & Company Inc. (NYSE: MRK) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $132.74 (-3.66% 1D, market cap $327.24B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, MRK ranks #55 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MRK compare to NVS and AZN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRK carries a Roarable C+ (69/100 RQD), trailing P/E of 19.8x, gross margin of 74.8%, and ROIC of 20.7%. By comparison, NVS (Novartis AG) holds a D+ grade (56/100 RQD, P/E 32.8x, ROIC 9.9%, cap $288.61B) and AZN (AstraZeneca PLC) posts a D+ grade (56/100 RQD, P/E 32.8x, ROIC 9.9%, cap $271.90B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MRK?
▼

Per MRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310158), Merck & Company Inc. generated $65.01B in revenue (+1.3% YoY), $18.25B in net income, and $12.36B in free cash flow against $136.87B in total assets and $46.75B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 MRK TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $MRK, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $MRK R/R 2.9 : 1 • RQD 69/100 (C+)
$MRK
Spot $132.74
1. GET IN (ENTRY)
$131.94–$133.40
2. HARD STOP (SUP)
$126.77 (-4.5%)
3. GET OUT (T1/T2)
$143.09 / $150.26
STOP-LOSS FLOOR (SUP $126.77): Hard stop sits 4.5% below spot to cap downside below key institutional support. If $MRK closes a daily candle below $126.77, step aside.
PROFIT TARGETS (RES $143.09 / $150.26): Scale out 50% at T1 (+7.8%) and trail stop to breakeven for T2 (+13.2%).
Want this $MRK sheet + Today's Top 3 Trades emailed free? Paper Trade $MRK →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $MRK Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $131.61 (-0.85%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 19% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C+ · Rk B
Cash (14)Whales (10)SEC (16)Macro (13)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$165 Bull$139 Base$109 Bear
📬 FREE MRK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRK)Realized 20D OHLCV Swing Band: ±3.9%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY MRK SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)

Altman Z-Score 5.19 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
77
Grade B+$146.94+0.7% Next Q
Q2 (-2Q)
74
Grade B+$148.04-0.2% Next Q
Q3 (-1Q)
72
Grade B$147.78-10.2% Next Q
Current
69
Grade C+$132.74+2% Hist 90D α
Trajectory: B+ (77) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MRK Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, MRK faces multiple-compression risk if 19.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 72.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($145.41) or 200D SMA ($129.91) invalidates the momentum regime and cuts Target Base ($139.31) toward Bear Floor ($108.66).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MRK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMOVERSOLD (<32)
26.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.19>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE60% OF RANGE
L: $96$132.74H: $157
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (74.8% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 26 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on MRK

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

20.7% ROIC with 74.8% gross margin and 3.42% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 5.19 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (65)

26/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like MRK
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (MRK Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MRK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.88%▼ SUPPORT BREAKDOWN
2026-11-22O $137.8H $137.8L $132.7C $132.7VOL 13.60M
$160.7$144.9$129.2$113.4$97.60RES $152.2SUP $137.0$132.72026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 20.7% vs WACC 6.6%)

MRK Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $176.89 vs Spot $132.74
SIGNIFICANTLY UNDERVALUED (+25.0%)
Undervalued Zone (< $150) Fair Value Corridor ($150–$203) Overvalued (> $203)
$133
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own MRK Growth & WACC Assumptions

YOUR DCF TARGET
$245.57
5-Yr Annual FCF Growth Rate: 13.6%
Discount Rate (WACC Hurdle): 6.6%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +25.0% vs $132.74 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.3%/yr Implied 5Y Growth

vs. +1.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MRK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MRK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRK)

Health Care Rank #55 of 1015 ⚔️ NVS vs MRK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MRK vs. NVS, AZN, ABBV, ABT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Merck & Company Inc. (MRK) ranks #55 by composite RQD confidence (69/100, grade C+) and #4 by equity capitalization ($327.24B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. ABBV currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with MRK at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MRK ACTIVE
Merck & Company Inc.
C+ 69/100 19.8x 74.8% 20.7% -3.66% $327.24B Benchmark Subject
NVS
Novartis AG
D+ 56/100 32.8x — 9.9% -2.55% $288.61B /nvs-vs-mrk →
AZN
AstraZeneca PLC
D+ 56/100 32.8x — 9.9% -1.91% $271.90B /azn-vs-mrk →
ABBV
AbbVie Inc.
B+ 76/100 121.6x 70.2% 29.0% -0.87% $501.14B /abbv-vs-mrk →
ABT
Abbott Laboratories
B 72/100 27.7x 56.4% 11.9% -0.49% $180.06B /abt-vs-mrk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000310158 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Merck & Company Inc. (MRK) reported GAAP revenue of $65.01B (+1.3% vs. FY2024 revenue of $64.17B , and +8.1% cumulative change since FY2023) , GAAP net income of $18.25B, operating cash flow of $16.47B, and free cash flow of $12.36B (-31.7% YoY). On the balance sheet, MRK closed FY2025 with $136.87B in total assets against $46.75B in total debt (Altman Z-Score: 5.19, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $65.01B $18.25B $16.47B $12.36B $136.87B $46.75B
FY2024 (FY) 2024-12-31 $64.17B $17.12B $21.47B $18.10B $117.11B $34.46B
FY2023 (FY) 2023-12-31 $60.12B $365.0M $13.01B $10.30B $198.56B $46.46B

3. MRK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, Merck & Company Inc. (NYSE: MRK) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $132.74 (-3.66% 1D, market cap $327.24B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, MRK ranks #55 in composite RQD confidence.

How does MRK compare to NVS and AZN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRK carries a Roarable C+ (69/100 RQD), trailing P/E of 19.8x, gross margin of 74.8%, and ROIC of 20.7%. By comparison, NVS (Novartis AG) holds a D+ grade (56/100 RQD, P/E 32.8x, ROIC 9.9%, cap $288.61B) and AZN (AstraZeneca PLC) posts a D+ grade (56/100 RQD, P/E 32.8x, ROIC 9.9%, cap $271.90B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MRK?

Per MRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310158), Merck & Company Inc. generated $65.01B in revenue (+1.3% YoY), $18.25B in net income, and $12.36B in free cash flow against $136.87B in total assets and $46.75B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MRK trading relative to its 50-day, 200-day, and 52-week technical levels?

MRK last traded at $132.74 (-3.66% on volume of 13,601,035 shares), positioning the stock -8.71% below its 50-day simple moving average ($145.41) and +2.18% above its 200-day simple moving average ($129.91). Across its 52-week range of $96.06 to $156.92, MRK sits at the 60.3% percentile with a 14-day RSI of 26.5 (OVERSOLD (<32)) and an implied next-earnings move of ±3.9% ($127.56 to $137.92).

ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

MRK — Merck & Company Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Merck & Company Inc. (MRK) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $132.74 (-3.66% 1D, market capitalization $327.24B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 20.7%, gross margin of 74.8%, operating margin of 34.3%, and free cash flow yield of 3.42%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 0.92x equity beta, Altman Z-Score of 5.19, Piotroski F-Score of 7/9, and Debt/Equity of 0.89x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Merck & Company Inc. Is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The company's gross margin of 74.8% and operating margin of 34.3% (per the market data) indicate a high-margin pharmaceutical profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Merck & Company Inc. (MRK) reported $65.01B in annual revenue (up from $64.17B in FY2024, +1.3% YoY) and $18.25B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($60.12B revenue, $365.0M net income) through FY2025, MRK scaled operating cash flow to $16.47B and free cash flow to $12.36B, backed by $136.87B in total assets against $46.75B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $96.06 – $156.92 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 19.8x trailing P/E and 15.3x EV/EBITDA against 34.3% operating margins and a 0.92x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context is the Health Care classification and the Biotechnology: Pharmaceutical Preparations industry label. The beta of 0.92 (per the market data) is the sole quantitative indication of market co-movement.

  • Key Question #1: Can MRK sustain or expand its 34.3% operating margin and 20.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $65.01B and free cash flow of $12.36B, how will capital allocation balance growth reinvestment against $46.75B in total debt?
  • Key Question #3: How sensitive is MRK's 18.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.92x)?

MRK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Merck & Company Inc. (MRK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MRK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MRK Bull vs. Bear Conversation Board — What's Your Call at $132.74?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MRK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $189.89 (+27.0%)
📌 Pinned Debate

The forensic balance sheet scores 16/20 with an Altman Z-Score of 5.19 and ROIC of 20.7%, indicating a financially sturdy company with

The forensic balance sheet scores 16/20 with an Altman Z-Score of 5.19 and ROIC of 20.7%, indicating a financially sturdy company with strong capital efficiency.. When you look under the hood at MRK, Fundamental Cash Engine is 14/20 with 74.8% gross margins and 20.7% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (19/20) has been quietly accumulating below $156.92. My 12M target is $189.89.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on 19.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (74.8%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $116.63 (-22.0%)
Spot @ $149.52

Free cash flow fell from $18.10B in FY 2024 to $12.36B in FY 2025 while debt rose from $34.46B to $46.75B, and the FCF yield of

Careful chasing MRK at $149.52. Free cash flow fell from $18.10B in FY 2024 to $12.36B in FY 2025 while debt rose from $34.46B to $46.75B, and the FCF yield of 3.42% offers a modest cash return at this valuation.. Gross margin is 74.8%, but operating margin is 34.3%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $116.63 on multiple compression.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
LIVE TAPE